查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1479062

全球體外毒理學測試市場評估依產品和服務,毒性終點和測試,方法,技術,最終用戶,地區,機會,預測 (2017-2031)

In-vitro Toxicology Testing Market Assessment, By Product and Services, By Toxicity Endpoint & Test, By Method, By Technology, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 245 Pages | 商品交期: 3-5個工作天內

價格

全球體外毒性測試市場規模預計將從 2023 年的 142.2 億美元增至 2031 年的 307.3 億美元，2024-2031 年預測期間複合年增長率為 10.11%。近年來市場呈現顯著成長，預計未來將維持穩定擴張速度。體外毒性測試允許在實驗室等受控環境中測試許多產品，包括各種化學物質、藥品和化妝品。開發早期階段的這一步驟對於瞭解化學生產物質的毒性至關重要，以便它們不會對消費者造成傷害。此測試評估化學物質、藥物和化妝品的安全性，無需施用於動物或人類。

由於許多對製藥、化學和化妝品行業有直接影響的因素，該市場正在呈現成長。世界各地政府機構不斷加強的監管分析和嚴格的安全評估是這個巨大市場的主要成長動力。這些措施使市場上的行業和企業能夠遵守嚴格的法規並採取措施確保產品安全。此外，高通量、3D 模型和器官晶片模型等技術進步已被證明可以在更短的時間內產生更可靠、更準確的結果。這使市場對其能力充滿信心並支持其成長。與行業巨頭的策略合作夥伴關係開發各種技術和藥品正在推動市場成長。

例如，2023 年 6 月，製藥、生物技術和營養保健市場的全球製造合作夥伴 Lonza 宣佈決定收購 Synaffix，這是一家專注於將用於開發抗體藥物綴合物的臨床階段技術平台商業化的公司。

新藥和化學品評估需求不斷增加

市場成長是由對新藥和化學品安全性評估的需求不斷增長所推動的。這些評估是由嚴格的監管要求所驅動的，這些要求要求進行全面的毒性評估。體外測試經濟高效，使您擺脫動物測試等傳統方法，並提供更快、更準確的產品洞察。高通量篩選和晶片器官模型等技術的進步使人們不再依賴動物測試等不道德的方法。這些新模型已被證明可以提高檢測的預測準確性和有效性。

此外，為了應對因備受矚目的藥物開發停止而引起的日益嚴重的安全問題，整個藥物開發過程中嚴格的安全性評估變得越來越重要。體外測試具有成本效益和時間效益，可促進更安全、更有效的治療方法的開發，以應對慢性病的流行和人口老化，從而推動製藥和生物技術行業的發展。

2022 年 10 月，Thermo Fisher Scientific Inc.宣佈將擴大在肯塔基州的業務，以協助客戶提供改變生活的藥物。目前的設施包括中心實驗室和生物標記服務，為生物製藥消費者提供高品質的實驗室服務以支援藥物開發。這幫助該公司擴大了在世界不同地區的診斷業務，並提高了其全球影響力。

技術進步

許多新開發的技術正在引入該市場，以提高檢測的預測準確性和相關性。高通量篩選、3D細胞培養和晶片器官等模型可以實現可靠的毒性評估，並提供不依賴動物實驗模型等傳統模型的平台。這些先進的模型使我們能夠刺激複雜的生理過程和器官間相互作用，同時提供對藥物毒性更與人類相關的理解。此外，將人工智慧整合到這些模型中將改善數據解釋和分析，幫助識別潛在的毒理學風險。自動化和機器人技術允許同時對大量化合物進行高通量篩選，徹底改變了體外毒性測試程序。

本報告研究和分析了全球體外毒性測試市場，提供市場規模和預測、市場動態以及主要參與者的現狀和前景。

目錄

第一章研究方法論

第二章 專案範圍與定義

第三章執行摘要

第四章 全球體外毒性測試市場展望（2017-2031）

  • 市場規模及預測
    • 金錢金額
    • 數量
  • 依產品/服務
    • 消耗品
    • 化驗
    • 服務
    • 機器
    • 軟件
  • 毒性終點/通過測試
    • 阿德梅
    • 皮膚刺激、腐蝕、致敏
    • 遺傳毒性
    • 細胞毒性
    • 眼毒性
    • 器官毒性
    • 光毒性
    • 皮膚毒性
    • 其他
  • 依方法
    • 細胞測定
    • 生化測定
    • 電腦模型
    • 分子毒性測試
    • 體外模型
  • 依技術
    • 細胞培養
    • 高通量
    • 毒物基因組學
    • 分子影像
  • 依最終用戶
    • 藥品、生物製藥
    • 化妝品、家居用品
    • 食品工業
    • 診斷
    • 化學工業
    • 其他
  • 依地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 市場佔有率：依公司劃分（2023 年）

第五章全球體外毒理學測試市場展望：依地區（2017-2031）

  • 北美
    • 市場規模及預測
    • 依產品/服務
    • 毒性終點/通過測試
    • 依方法
    • 依技術
    • 依最終用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印度尼西亞
    • 菲律賓
  • 南美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合酋長國
    • 南非

第六章 市場測繪（2023）

  • 依產品/服務
  • 毒性終點/通過測試
  • 依方法
  • 依技術
  • 依最終用戶
  • 依地區

第七章 宏觀環境與產業結構

  • 供需分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第八章市場動態

  • 增長動力
  • 成長限制因素（問題、限制因素）

第九章 監理框架，創新

  • 臨床試驗
  • 專利情況
  • 創新/新技術

第十章 主要公司情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 名市場領導者的市場收入分析（2023 年）
  • 併購/合資（如適用）
  • SWOT 分析（5 家市場公司）
  • 專利分析（如果適用）

第11章價格分析

第十二章案例研究

第十三章 主要公司展望

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Eurofins Scientific
  • Evotec S.E.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Societe Generale de Surveillance SA
  • Thermo Fisher Scientific Inc

第十四章 戰略建議

第十五章 關於我們公司、免責聲明

Product Code: MX11313

Global in-vitro toxicology testing market is projected to witness a CAGR of 10.11% during the forecast period 2024-2031, growing from USD 14.22 billion in 2023 to USD 30.73 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. In-vitro toxicology testing enables testing of various chemicals, drugs, cosmetics and many other products in a controlled environment such as a laboratory. This step in the earlier stages of development is mandatory to know the toxicity of any chemically made substance so that it is not harmful for the consumers. This test evaluates the safety of any chemicals, drugs, or cosmetics without subjecting them to any animals or humans.

The in-vitro toxicology testing market is witnessing growth driven by many factors directly affecting the pharmaceutical, chemical and cosmetics industries. Increasing regulatory analysis and stringent safety evaluations imposed by governmental bodies worldwide are the main factors fueling the growth of this huge market. These measures make industries and players in its market comply with strict regulations and enable them to follow a procedure that ensures the safety of the product. Additionally, advancements in technology such as high-throughput and 3D models, organ-on-a-chip models, have proven to offer much more reliable and accurate results in less times. It has given the market confidence to function, hence supporting its growth. Strategic partnerships between industry giants to develop different technologies and drugs is driving the market growth.

For instance, in June 2023, a global manufacturing partner of pharmaceutical, biotech, and nutraceutical markets, Lonza announced its decision to acquire Synaffix which focuses on commercializing its clinical-stage technology platform for developing antibody-drug conjugates.

Rising Demand for Assessment of New Drugs and Chemicals

The growth of in-vitro toxicology testing market is fueled by increasing demand for safety assessments of new drug and chemicals. These assessments are driven by stringent regulatory requirements mandating comprehensive toxicity evaluations. In-vitro testing is cost-effective and efficient and saves us from the old methods such as animal testing and provides us with quick and more accurate insights for our product. Technological advancements like that of high-throughput screening and organ-on-a-chip models have given us the freedom to not rely on unethical methods such as that of animal-testing. These new models have been proven to enhance the predictive accuracy and relevance of assays.

Moreover, rigorous safety assessments have become increasingly important throughout the drug development process following the increased safety concerns for high-profile drug withdrawals. In-vitro testing offers cost and time efficiencies and supports the pharmaceutical and biotechnology industries' robust growth by facilitating the development of safer and more effective therapeutic agents to address the increasing prevalence of chronic diseases and aging populations.

In October 2022, Thermo Fisher Scientific Inc. announced that they will expand operations in Kentucky to help customers by delivering life-changing medicines to patients. The current facility includes central lab and biomarker services, providing biopharma consumers with high-quality lab work to boost drug development. It has helped the company expand its diagnostics business across various regions in the world and helped increase its global presence.

Technological Advancements

Many newly developed technologies have been introduced to this market to enhance the predictive accuracy and relevance of assays. Models such as high-throughput screening, 3D cell culture, and organ-on-a-chip have enabled reliable toxicity assessments giving us the platform to be able to not rely on traditional models like that of animal testing models. These advanced models allow stimulation of complex physiological processes and organ interactions, while providing a more human-relevant understanding of drug toxicity. Additionally, integration of AI with these models improves the data interpretation and analysis which is helpful in identifying any potential toxicological risks. Automation and robotics have revolutionized the procedure of in-vitro toxicology testing by enabling high-throughput screening of a large number of compounds simultaneously.

The adoption of stringent guidelines, standardized protocols, and regulations ensure consistency and reproducibility across assays, strengthening their acceptance by regulatory agencies and pharmaceuticals. It underscores the importance of in-vitro testing in the early stages of drug development and ensures the market of in-vitro toxicology testing is driven by expansion of its applications during pre-clinical trials and drug screening. Thermo Fisher Scientific launched the first of 37 CE-IVD- marked real-time PCR assay kits in April 2023 for infectious diseases. These assays were available in countries recognizing CE marking for use with the CE-IVD marked QS5 Dx, a diagnostic testing platform compliant with the EU's new in-vitro medical devices regulation framework.

Dominance of Cell Culture Technology

In-vitro toxicology testing market is experiencing robust growth due to advancing cell culture technology. The advancements in cell culture technology are driving the in-vitro toxicology testing market with its ability to provide predictive, demonstrative, and reliable results while toxicity screening of a wide range of chemicals, including nanomaterials and airborne materials. The advancements have enabled the expansion of the toxicology testing market as it involves using cells and tissues grown and maintained in controlled environments inside laboratories. Toxic properties of any drug or chemical can be examined easily.

For instance, Xenobiotics can be examined at the basic level of cell without involving the interplay of complex physiological systemic effects. Cellular assays can be easily integrated with technology such as high throughput formats or 3D formats enabling faster screening of large numbers of compounds for potential toxicity. The level of efficiency and accuracy is important on a large scale for pharmaceutical industries, biotechnology companies, or any company developing chemically related substances.

On November 17, 2023, the University of Texas MD Anderson Cancer Centre and Toppan Holdings signed a research collaboration agreement to assess Toppan Holdings' cell culture technology to advance personalized medicine and drug screening initiatives. During the three-year partnership, patient-derived tumor tissue will be used to produce in vitro "cancer patient avatars" utilizing Toppan Holdings' exclusive 3D cell culture technology, Invivoid. The avatars will be given anticancer medications, and the therapeutic usefulness of this technique for determining medication efficacy will be evaluated.

North America Will Dominate In-vitro Toxicology Testing Market Share

North America is anticipated to dominate the global market share over the forecast period in the in-vitro toxicology testing market. Due to the rising burden of chronic diseases and population in North America, healthcare-related engagement is increasing, which encourages more R&D of drugs and vaccines. North America is experiencing a significant increase in different diseases that can be treated or managed with drugs.

For instance, about 2.4 million Canadians have a heart disease according to a report by Canadian Institute for Health Information updated in June 2022. According to a report by Spotlight on Heart failure published in 2022, more than 100,000 Canadians are likely to be diagnosed with heart failure each year. North America, being a hub of healthcare and pharmaceutical companies expedites innovation and product launches which enables growth in research and development activities. Evotec announced in February 2023 about the relocation of its subsidiary, Cyprotex US, LLC, from Watertown to Framingham, U.S. It was done to expand the new facility to enable faster turnaround times.

Future Market Scenario (2024 - 2031F)

Increasing prevalence of various chronic diseases is the biggest reason behind the growth of in-vitro toxicology testing market. For management and treatment of diseases a lot of R&D is required to develop a drug with high clinical efficacy. Rapidly developing healthcare and biotechnological forums present an evergreen opportunity for the global in-vitro toxicology testing market value to grow and multiply manifolds. The scope of the market extends beyond pharmaceutical industry. Scientists, biotechnologists, healthcare professionals, and other healthcare professionals in the industry are dedicated towards introducing advanced technologies and modern diagnostic techniques which will contribute towards market growth.

For instance, Eurofins Scientific in January 2023, expanded its presence in India with the establishment of a new, fully equipped, state-of-the-art laboratory campus in Hyderabad. The lab is aimed at supporting pharma and biotechnology companies in the domain of synthetic organic chemistry, analytical R&D, bioanalytical services, in vivo pharmacology safety toxicology, and formulation R&D.

Key Players Landscape and Outlook

Several companies are expanding their business by planning and adopting new strategies. Companies are forming strategic partnerships to increase their presence in different geographies. Product launches, distribution agreements, mergers and acquisitions, and investments, and partnerships are some of the strategies being followed by leading pharmaceutical and biotechnology companies.

Agilent Technologies (US) acquired e-MSion (US) in March 2023. Through this acquisition, they plan to integrate the e-MSion's ExD cell into portfolio of advanced workflows, instruments, and analytical solutions for biotherapeutic characterization and development.

In August 2023, Evotec announced its partnership with STORM, the world's leading small RNA molecule modifying enzyme drug discovery company. They aimed to present the discovery of STORM's leading clinical candidate, STC-15. STC-15 is a highly selective, orally bioavailable, and RME inhibitor for METTL3, which was developed by both STORM and Evotec.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global In-vitro Toxicology Testing Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Product and Services
    • 4.2.1.Consumables
    • 4.2.2.Assays
      • 4.2.2.1.Bacterial Toxicity Assays
      • 4.2.2.2.Enzyme Toxicity Assays
      • 4.2.2.3.Cell-Based Elisa & Western Blotting Assays
      • 4.2.2.4.Receptor Binding Assays
      • 4.2.2.5.Tissue Culture Assays
      • 4.2.2.6. Other Assays
    • 4.2.3.Services
    • 4.2.4.Equipment
    • 4.2.5.Software
  • 4.3.By Toxicity Endpoint & Test
    • 4.3.1.ADME (Absorption, Distribution, Metabolism, and Excretion)
    • 4.3.2.Skin Irritation, Corrosion, Sensitization
    • 4.3.3.Genotoxicity
    • 4.3.4.Cytotoxicity
    • 4.3.5.Ocular Toxicity
    • 4.3.6.Organ Toxicity
    • 4.3.7.Phototoxicity
    • 4.3.8.Dermal Toxicity
    • 4.3.9.Others
  • 4.4.By Method
    • 4.4.1.Cellular Assays
    • 4.4.2.Biochemical Assays
    • 4.4.3.In Silico Models
    • 4.4.4.Molecular Toxicology Assays
    • 4.4.5.Ex vivo Models
  • 4.5.By Technology
    • 4.5.1.Cell Culture
    • 4.5.2.High Throughput
    • 4.5.3.Toxicogenomic
    • 4.5.4.Molecular Imaging
  • 4.6.By End-user
    • 4.6.1.Pharmaceuticals and Biopharmaceuticals
    • 4.6.2.Cosmetics and Household Products
    • 4.6.3.Food Industry
    • 4.6.4.Diagnostics
    • 4.6.5.Chemical Industry
    • 4.6.6.Others
  • 4.7.By Region
    • 4.7.1.North America
    • 4.7.2.Europe
    • 4.7.3.Asia-Pacific
    • 4.7.4.South End-user America
    • 4.7.5.Middle East and Africa
  • 4.8.By Company Market Share (%), 2023

5.Global In-vitro Toxicology Testing Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Product and Services
      • 5.1.2.1.Consumables
      • 5.1.2.2.Assays
        • 5.1.2.2.1.Bacterial Toxicity Assays
        • 5.1.2.2.2.Enzyme Toxicity Assays
        • 5.1.2.2.3.Cell-Based Elisa & Western Blotting Assays
        • 5.1.2.2.4.Receptor Binding Assays
        • 5.1.2.2.5.Tissue Culture Assays
        • 5.1.2.2.6. Other Assays
      • 5.1.2.3.Services
      • 5.1.2.4.Equipment
      • 5.1.2.5.Software
    • 5.1.3.By Toxicity Endpoint & Test
      • 5.1.3.1.ADME (Absorption, Distribution, Metabolism, and Excretion)
      • 5.1.3.2.Skin Irritation, Corrosion, Sensitization
      • 5.1.3.3.Genotoxicity
      • 5.1.3.4.Cytotoxicity
      • 5.1.3.5.Ocular Toxicity
      • 5.1.3.6.Organ Toxicity
      • 5.1.3.7.Phototoxicity
      • 5.1.3.8.Dermal Toxicity
      • 5.1.3.9.Others
    • 5.1.4.By Method
      • 5.1.4.1.Cellular Assays
      • 5.1.4.2.Biochemical Assays
      • 5.1.4.3.In Silico Models
      • 5.1.4.4.Molecular Toxicology Assays
      • 5.1.4.5.Ex vivo Models
    • 5.1.5.By Technology
      • 5.1.5.1.Cell Culture
      • 5.1.5.2.High Throughput
      • 5.1.5.3.Toxicogenomic
      • 5.1.5.4.Molecular Imaging
    • 5.1.6.By End-user
      • 5.1.6.1.Pharmaceuticals and Biopharmaceuticals
      • 5.1.6.2.Cosmetics and Household Products
      • 5.1.6.3.Food Industry
      • 5.1.6.4.Diagnostics
      • 5.1.6.5.Chemical Industry
      • 5.1.6.6.Others
    • 5.1.7.United States*
      • 5.1.7.1.Market Size & Forecast
        • 5.1.7.1.1.By Value
        • 5.1.7.1.2.By Volume
      • 5.1.7.2.By Product and Services
        • 5.1.7.2.1.Consumables
        • 5.1.7.2.2.Assays
          • 5.1.7.2.2.1.Bacterial Toxicity Assays
          • 5.1.7.2.2.2.Enzyme Toxicity Assays
          • 5.1.7.2.2.3.Cell-Based Elisa & Western Blotting Assays
          • 5.1.7.2.2.4.Receptor Binding Assays
          • 5.1.7.2.2.5.Tissue Culture Assays
          • 5.1.7.2.2.6. Other Assays
        • 5.1.7.2.3.Services
        • 5.1.7.2.4.Equipment
        • 5.1.7.2.5.Software
      • 5.1.7.3.By Toxicity Endpoint & Test
        • 5.1.7.3.1.ADME (Absorption, Distribution, Metabolism, and Excretion)
        • 5.1.7.3.2.Skin Irritation, Corrosion, Sensitization
        • 5.1.7.3.3.Genotoxicity
        • 5.1.7.3.4.Cytotoxicity
        • 5.1.7.3.5.Ocular Toxicity
        • 5.1.7.3.6.Organ Toxicity
        • 5.1.7.3.7.Phototoxicity
        • 5.1.7.3.8.Dermal Toxicity
        • 5.1.7.3.9.Others
      • 5.1.7.4.By Method
        • 5.1.7.4.1.Cellular Assays
        • 5.1.7.4.2.Biochemical Assays
        • 5.1.7.4.3.In Silico Models
        • 5.1.7.4.4.Molecular Toxicology Assays
        • 5.1.7.4.5.Ex vivo Models
      • 5.1.7.5.By Technology
        • 5.1.7.5.1.Cell Culture
        • 5.1.7.5.2.High Throughput
        • 5.1.7.5.3.Toxicogenomic
        • 5.1.7.5.4.Molecular Imaging
      • 5.1.7.6.By End-user
        • 5.1.7.6.1.Pharmaceuticals and Biopharmaceuticals
        • 5.1.7.6.2.Cosmetics and Household Products
        • 5.1.7.6.3.Food Industry
        • 5.1.7.6.4.Diagnostics
        • 5.1.7.6.5.Chemical Industry
        • 5.1.7.6.6.Others
    • 5.1.8.Canada
    • 5.1.9.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Product and Services
  • 6.2.By Toxicity Endpoint & Test
  • 6.3.By Method
  • 6.4.By Technology
  • 6.5.By End-user
  • 6.6.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Abbott Laboratories
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Agilent Technologies, Inc.
  • 13.3.Bio-Rad Laboratories, Inc.
  • 13.4.Catalent, Inc.
  • 13.5.Charles River Laboratories International, Inc.
  • 13.6.Danaher Corporation
  • 13.7.Eurofins Scientific
  • 13.8.Evotec S.E.
  • 13.9.Laboratory Corporation of America Holdings
  • 13.10.Merck KGaA
  • 13.11.Societe Generale de Surveillance SA
  • 13.12.Thermo Fisher Scientific Inc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 4.Global In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 5.Global In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 6.Global In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 7.Global In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 8.Global In-vitro Toxicology Testing Market Share (%), By Region, 2017-2031F
  • Figure 9.North America In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 10.North America In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 11.North America In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 12.North America In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 13.North America In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 14.North America In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 15.North America In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 16.North America In-vitro Toxicology Testing Market Share (%), By Country, 2017-2031F
  • Figure 17.United States In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 18.United States In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 19.United States In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 20.United States In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 21.United States In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 22.United States In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 23.United States In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 24.Canada In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 25.Canada In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 26.Canada In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 27.Canada In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 28.Canada In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 29.Canada In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 30.Canada In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 31.Mexico In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 32.Mexico In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 33.Mexico In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 34.Mexico In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 35.Mexico In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 36.Mexico In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 37.Mexico In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 38.Europe In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 39.Europe In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 40.Europe In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 41.Europe In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 42.Europe In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 43.Europe In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 44.Europe In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 45.Europe In-vitro Toxicology Testing Market Share (%), By Country, 2017-2031F
  • Figure 46.Germany In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.Germany In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.Germany In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 49.Germany In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 50.Germany In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 51.Germany In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 52.Germany In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 53.France In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 54.France In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 55.France In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 56.France In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 57.France In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 58.France In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 59.France In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 60.Italy In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 61.Italy In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 62.Italy In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 63.Italy In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 64.Italy In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 65.Italy In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 66.Italy In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 67.United Kingdom In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 68.United Kingdom In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 69.United Kingdom In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 70.United Kingdom In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 71.United Kingdom In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 72.United Kingdom In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 73.United Kingdom In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 74.Russia In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 75.Russia In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 76.Russia In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 77.Russia In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 78.Russia In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 79.Russia In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 80.Russia In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 81.Netherlands In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 82.Netherlands In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 83.Netherlands In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 84.Netherlands In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 85.Netherlands In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 86.Netherlands In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 87.Netherlands In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 88.Spain In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Spain In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Spain In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 91.Spain In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 92.Spain In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 93.Spain In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 94.Spain In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 95.Turkey In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 96.Turkey In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 97.Turkey In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 98.Turkey In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 99.Turkey In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 100.Turkey In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 101.Turkey In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 102.Poland In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 103.Poland In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 104.Poland In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 105.Poland In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 106.Poland In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 107.Poland In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 108.Poland In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 109.South America In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 110.South America In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 111.South America In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 112.South America In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 113.South America In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 114.South America In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 115.South America In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 116.South America In-vitro Toxicology Testing Market Share (%), By Country, 2017-2031F
  • Figure 117.Brazil In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 118.Brazil In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 119.Brazil In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 120.Brazil In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 121.Brazil In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 122.Brazil In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 123.Brazil In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 124.Argentina In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 125.Argentina In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 126.Argentina In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 127.Argentina In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 128.Argentina In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 129.Argentina In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 130.Argentina In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 131.Asia-Pacific In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 132.Asia-Pacific In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 133.Asia-Pacific In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 134.Asia-Pacific In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 135.Asia-Pacific In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 136.Asia-Pacific In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 137.Asia- Pacific In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 138.Asia-Pacific In-vitro Toxicology Testing Market Share (%), By Country, 2017-2031F
  • Figure 139.India In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 140.India In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 141.India In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 142.India In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 143.India In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 144.India In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 145.India In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 146.China In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 147.China In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 148.China In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 149.China In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 150.China In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 151.China In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 152.China In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 153.Japan In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 154.Japan In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 155.Japan In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 156.Japan In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 157.Japan In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 158.Japan In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 159.Japan In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 160.Australia In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 161.Australia In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 162.Australia In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 163.Australia In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 164.Australia In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 165.Australia In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 166.Australia In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 167.Vietnam In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 168.Vietnam In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 169.Vietnam In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 170.Vietnam In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 171.Vietnam In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 172.Vietnam In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 173.Vietnam In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 174.South Korea In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 175.South Korea In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 176.South Korea In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 177.South Korea In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 178.South Korea In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 179.South Korea In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 180.South Korea In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 181.Indonesia In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.Indonesia In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.Indonesia In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 184.Indonesia In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 185.Indonesia In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 186.Indonesia In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 187.Indonesia In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 188.Philippines In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 189.Philippines In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 190.Philippines In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 191.Philippines In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 192.Philippines In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 193.Philippines In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 194.Philippines In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 195.Middle East & Africa In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 196.Middle East & Africa In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 197.Middle East & Africa In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 198.Middle East & Africa In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 199.Middle East & Africa In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 200.Middle East & Africa In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 201.Middle East & Africa In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 202.Middle East & Africa In-vitro Toxicology Testing Market Share (%), By Country, 2017-2031F
  • Figure 203.Saudi Arabia In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 204.Saudi Arabia In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 205.Saudi Arabia In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 206.Saudi Arabia In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 207.Saudi Arabia In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 208.Saudi Arabia In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 209.Saudi Arabia In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 210.UAE In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 211.UAE In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 212.UAE In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 213.UAE In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 214.UAE In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 215.UAE In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 216.UAE In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 217.South Africa In-vitro Toxicology Testing Market, By Value, In USD Billion, 2017-2031F
  • Figure 218.South Africa In-vitro Toxicology Testing Market, By Volume, In Million Units, 2017-2031F
  • Figure 219.South Africa In-vitro Toxicology Testing Market Share (%), By Product and Services, 2017-2031F
  • Figure 220.South Africa In-vitro Toxicology Testing Market Share (%), By Toxicity Endpoint & Test, 2017-2031F
  • Figure 221.South Africa In-vitro Toxicology Testing Market Share (%), By Method, 2017-2031F
  • Figure 222.South Africa In-vitro Toxicology Testing Market Share (%), By Technology, 2017-2031F
  • Figure 223.South Africa In-vitro Toxicology Testing Market Share (%), By End-user, 2017-2031F
  • Figure 224.By Product and Services Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225.By Toxicity Endpoint & Test Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226.By Method Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227.By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023